Your browser doesn't support javascript.
loading
Robot-assisted partial nephrectomy in morbidly obese patients: a VCQI database study.
Sharma, Gopal; Singh, Gurpremjit; Ahluwalia, Puneet; Dasgupta, Prokar; Challacombe, Benjamin J; Bhandari, Mahendra; Ahlawat, Rajesh; Rawal, Sudhir; Buffi, Nicolo M; Ananth, Sivaraman; Porter, James R; Rogers, Craig; Mottrie, Alexandre; Abaza, Ronney; Rha, Khoon Ho; Moon, Daniel; Yuvaraja, Thyavihally B; Parekh, Dipen J; Capitanio, Umberto; Maes, Kris K; Porpiglia, Francesco; Turkeri, Levent; Gautam, Gagan.
Afiliação
  • Sharma G; Department of Urologic Oncology, Medanta The Medicity, Gurgaon, India. gopal.26669192@gmail.com.
  • Singh G; Department of Urologic Oncology, Medanta The Medicity, Gurgaon, India.
  • Ahluwalia P; Department of Urologic Oncology, Medanta The Medicity, Gurgaon, India.
  • Dasgupta P; Faculty of Life Sciences and Medicine, King's College, King's Health Partners, London, UK.
  • Challacombe BJ; Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK.
  • Bhandari M; Vattikuti Foundation, Detroit, MI, USA.
  • Ahlawat R; Medanta the Medicity, The Medicity Hospital, Gurugram, New Delhi, India.
  • Rawal S; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
  • Buffi NM; Humanitas Research Hospital, Rozzano, MI, Italy.
  • Ananth S; Chennai Urology and Robotics Institute, Apollo Hospitals, Greams Lane, Chennai, India.
  • Porter JR; Swedish Medical Center, Seattle, WA, USA.
  • Rogers C; Henry Ford Hospital, Detroit, MI, USA.
  • Mottrie A; ORSI Academy, Melle, Belgium.
  • Abaza R; Central Ohio Urology Group and Mount Carmel, St. Ann's Hospital, Columbus, OH, USA.
  • Rha KH; Yonsei University Health System, Seoul, South Korea.
  • Moon D; Peter MacCallum Cancer Centre, Peter MacCallum Hospital, Royal Melbourne Clinical School, University of Melbourne, Melbourne, Australia.
  • Yuvaraja TB; Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.
  • Parekh DJ; University of Miami Health System, Miami, FL, USA.
  • Capitanio U; Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Milan, Italy.
  • Maes KK; Center for Robotic and Minimally Invasive Surgery, Hospital Da Luz, Luz Sáude, Portugal.
  • Porpiglia F; San Luigi Gonzaga Hospital of Orbassano, Turin, Italy.
  • Turkeri L; Department of Urology, Altuzinade Hospital, Acibadem M.A., Aydinlar University, Istanbul, Turkey.
  • Gautam G; Department of Urologic Oncology, Medanta The Medicity, Gurgaon, India.
J Robot Surg ; 17(5): 2141-2147, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37248374
ABSTRACT
To compare perioperative outcomes following robot-assisted partial nephrectomy (RAPN) in patients with morbid obesity (body mass index (BMI > 40 kg/m2)) and non-obese patients. Using the Vattikuti Collective quality initiative (VCQI) database for RAPN, data for morbidly obese and non-obese patients was obtained. Propensity scores were calculated for two treatment groups (morbidly obese vs. non-obese) for the following variables i.e. age, sex, tumor size, RNS, surgical access (retroperitoneal/transperitoneal) and estimated glomerular filtration rate (eGFR) to ensure comparability. The primary outcome for the study was comparison of trifecta between the two groups. In this study, 158 morbidly obese patients were matched with 158 non-obese patients undergoing RAPN. Two groups matched well for age, sex, tumor size, eGFR and RNS. There was no difference between two groups for ischemia time, blood loss, blood transfusion, conversion to radical nephrectomy, length of stay, intraoperative and postoperative complications. Operative time was longer in morbidly obese patients (median 210 min vs. 120 min, p = 0.000). On pathological analysis, malignant tumors were more likely in the morbidly obese group (83.1% vs.73.4%, p = 0.018). Trifecta outcomes were comparable between the two groups (60.1% vs. 63.3%, p = 0.563). The Median duration of follow-up was 12 months (1-96 months). The morbidly obese group had significantly higher day one creatinine (1.25 ± 0.7 vs. 1.07 ± 0.37, p = 0.001) and significantly lower day one eGFR (62.1 ± 19 vs. 69.2 ± 21, p = 0.018). However, there was no difference between the two groups for the last follow-up creatinine and eGFR. RAPN in morbidly obese patients is associated with equivalent perioperative outcomes compared to non-obese patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Obesidade Mórbida / Robótica / Procedimentos Cirúrgicos Robóticos / Neoplasias Renais Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Obesidade Mórbida / Robótica / Procedimentos Cirúrgicos Robóticos / Neoplasias Renais Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article